Jiménez-Vicente, C, Arribas, I, Pomares, H, Ramil, G, Castaño-Diez, S, Pérez-Valencia, AI, Sturla, AL, López-Guerra, M, Martinez-Roca, A, Zugasti, I, Guijarro, F, Cortés-Bullich, A, Merchán, B, Triguero, A, Monge, I, Tuca, A, Oñate, G, Garrido, A, Sierra, J, Arnan, M, Esteve, J, Díaz-Beyá, M. Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia. HAEMATOLOGICA. 2025; 110(6)DOI:10.3324/haematol.2024.286589. PMID:39844754. IF:10.100(Q1/2D).

Jimenez-Vicente, C, Cardus, A, Castaño-Diez, S, Ramil, G, Garcia-Avila, S, Gomez-Perez, L, Esteban, D, Arribas, I, Sturla, AL, Lopez-Guerra, M, Martinez-Roca, A, Cortes-Bullich, A, Perez-Valencia, AI, Zugasti, I, Monge, I, Carcelero, E, Vall-Llovera, F, Vives, S, Sierra, J, Nomdedeu, J, Oñate, G, Garrido, A, Pratcorona, M, Pomares, H, Arnan, M, Guijarro, F, Diaz-Beya, M, Esteve, J. Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations. Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-025-01298-6. PMID:40368916. IF:11.600(Q1/1D).

Sobas, MA, Turki, AT, Ramiro, AV, Hernández-Sánchez, A, Elicegui, JM, González, T, Melchor, RA, Abáigar, M, Tur, L, Dall'Olio, D, Sträng, E, Tettero, JM, Castellani, G, Benner, A, Doehner, K, Thiede, C, Metzeler, KH, Haferlach, T, Damm, F, Ayala, R, Martínez-López, J, Mills, KI, Sierra, J, Lehmann, S, Della Porta, MG, Mayer, J, Reinhardt, D, Medina, RV, Schulze-Rath, R, Barbus, M, Hernández-Rivas, JM, Huntly, BJP, Ossenkoppele, G, Döhner, H, Bullinger, L. Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance. HAEMATOLOGICA. 2025; 110(5)DOI:10.3324/haematol.2024.285805. PMID:39506894. IF:10.100(Q1/2D).

Lambert, N, Forte, F, El Moussaoui, M, Monseur, J, Raus, N, Polushin, A, Michonneau, D, Shultz, C, Hogan, WJ, Balaguer-Roselló, A, Gil-Perotín, S, Brijs, J, Chauvet, P, Gavriilaki, M, Carre, M, Dulamea, AO, Chalandon, Y, Salmenniemi, U, Duminuco, A, Ram, R, García-Cadenas, I, Porto, G, Nguyen, S, Smallbone, P, González-Vicent, M, Santoro, JD, Willems, E, Baron, F, Servais, S, Beguin, Y, Maquet, P, CNS GvHD Study Grp. CNS manifestations in acute and chronic graft-versus-host disease. BRAIN. 2025; 148(4)DOI:10.1093/brain/awae340. PMID:39442000. IF:11.700(Q1/1D).